

[From the Journal of the American Medical Association, Vol. 208, No. 7, May 19, 1969, pp. 1171-1172]

WHITE PAPER ON THE THERAPEUTIC EQUIVALENCE OF CHEMICALLY EQUIVALENT* DRUGS—SPECIAL COMMUNICATION

(Prepared by a Subcommittee of the Policy Advisory Committee, Drug Efficacy Study)

Recent reports of considerable variation in the serum levels, and therefore in the probable biological activities, of equal doses of certain drugs marketed by different manufacturers, focus attention upon an important determinant of drug efficacy. These variations indicate that therapeutic equivalence, or equal biological activity, cannot necessarily be inferred from equivalence in the chemical constitution of different formulations of the same drug. In the Drug Efficacy Study, it has been found that, in many cases, no data bearing on biological activity of chemically equivalent drugs are available other than those submitted by the manufacturer who originally filed a New Drug Application for his product. For this reason, the following qualifying addendum was approved by the Policy Advisory Committee of the Drug Efficacy Study and was forwarded to the Food and Drug Administration with each of the 26 groups.

"Drugs of identical chemical composition (so-called generic drugs) formulated and marketed by numerous individual firms under generic or trademarked names have been evaluated for efficacy as a group without consideration of "therapeutic equivalence." In the event that no evidence for pharmacological availability or therapeutic efficacy in man can be presented for any of the drugs in the attached listing, their classifications of effectiveness may need to be modified if future regulations of the FDA requires such proof."

This statement defines the problem but offers no solution. Theoretically, biological tests in man of every formulation of a drug would be needed in order to establish proof of therapeutic equivalency. In many but not all instances, blood levels might be a satisfactory index of therapeutic activity as well as of the absorption of oral preparations. Furthermore, if appropriate chemical or physical tests should be found to correlate consistently with serum concentrations, these in vitro tests might be substituted for the more burdensome tests in animals or man. Indeed, blood levels in animals can be acceptable tests only if they correlate with comparable observations in man. The more potent the pharmacodynamic action of the drug, the more imperative would be the need for proof of the equivalence of biological and physical or chemical tests.

The Policy Advisory Committee of the Drug Efficacy Study is aware that consistent evidence of therapeutic equivalence of oral preparations, even when based upon simple study of blood concentrations in man, might require the testing of each lot of each formulation and so become a large-scale clinical operation requiring consent of large numbers of patients and volunteers. A strict interpretation of therapeutic equivalence might even require biological tests of individual capsules or successive batches of the drug selected at random.

Moreover, variation in biological response of individual subjects would seem likely to be greater than compositional differences among enteric-coated tablets or timed-release capsules. Let us not deceive ourselves: if tests in human subjects constitute the only reliable method of demonstrating therapeutic equivalence, an unacceptably large burden will be imposed on drug manufacturers. Such biological tests may represent the most valid measure of comparative therapeutic activities, but the measure is one that is impossible of technical achievement by the pharmaceutical and medical professions.

What, in this less than perfect world, can be done? All producers of drugs should be required, as they are now, not only to provide evidence of composition, purity, and quality but also evidence of physical availability as judged by tests of disintegration, dispersion, and dissolution rates in appropriate solvents. In the majority of cases, this should suffice, but in every case in which there may

*Drugs that meet the current standards of identity, purity, and quality, and quality of the active ingredients established by competent authority.